Conditions:   Ovarian Cancer;   Ovarian Carcinoma;   Recurrent Ovarian Cancer;   Recurrent Ovarian Carcinoma
Interventions:   Radiation: Low Dose Fractionated Whole Abdominal Radiation Therapy;   Drug: Carboplatin;   Drug: Docetaxel
Sponsor:   University of Miami Sylvester Comprehensive Cancer Center
Not yet recruiting - verified March 2014

Condition:   Prostate Cancer Metastatic
Interventions:   Drug: CABAZITAXEL XRP6258;   Drug: Prednisone;   Drug: Prednisolone
Sponsor:   Sanofi
Not yet recruiting - verified February 2014

Condition:   Oligo-metastatic Stage IV Non-small Cell Lung Cancer（NSCLC）
Interventions:   Radiation: concurrent chemoradiotherapy;   Drug: Docetaxel;   Drug: pemetrexed;   Drug: Cisplatin
Sponsors:   Sichuan Cancer Hospital and Research Institute;   gansu cancer hospital;   Mianyang central hospital;   Cancer Hospital of Guizhou Province
Recruiting - verified February 2014

Condition:   Breast Cancer
Interventions:   Drug: Anthracycline based chemotherapy;   Drug: taxane-based chemotherapy
Sponsors:   The Methodist Hospital System;   GE Healthcare
Recruiting - verified February 2014

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Erlotinib;   Drug: Chemotherapy
Sponsors:   Finnish Lung Cancer Group;   Roche Pharma AG
Recruiting - verified February 2014

Condition:   Squamous Cell Carcinoma of Head and Neck
Interventions:   Drug: Cisplatin;   Drug: DOCETAXEL XRP6976;   Drug: Dexamethasone;   Drug: Dexamethasone
Sponsor:   Sanofi
Not yet recruiting - verified February 2014

Conditions:   Recurrent;   Head and Neck Cancer
Interventions:   Radiation: SBRT;   Drug: Cetuximab;   Drug: Docetaxel
Sponsor:   University of Pittsburgh
Recruiting - verified February 2014

Condition:   Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
Interventions:   Drug: Aldoxorubicin;   Drug: Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
Sponsor:   CytRx
Not yet recruiting - verified January 2014

Condition:   Head and Neck Neoplasms
Intervention:  
Sponsor:   Chinese PLA General Hospital
Recruiting - verified January 2014

Condition:   Locally Advanced Gastric Carcinoma
Interventions:   Biological: Bevacizumab;   Drug: docetaxel oxaliplatin 5-FU CF;   Procedure: Gastrectomy
Sponsor:   Chinese PLA General Hospital
Completed - verified January 2014

Condition:   Metastatic Castration-resistant Prostate Cancer
Interventions:   Drug: Taxotere;   Drug: Jevtana
Sponsors:   Gustave Roussy, Cancer Campus, Grand Paris;   Sanofi
Recruiting - verified January 2014

Condition:   Metastatic Breast Cancer
Intervention:   Drug: Docetaxel
Sponsor:   Centro Universitario contra el Cáncer
Active, not recruiting - verified January 2014

Condition:   Colorectal Cancer
Interventions:   Drug: Dacomitinib;   Drug: PD-0325901;   Drug: Irinotecan;   Drug: Docetaxel;   Drug: Capecitabine
Sponsors:   The Netherlands Cancer Institute;   Pfizer
Recruiting - verified January 2014

Conditions:   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions:   Drug: sorafenib tosylate;   Drug: cisplatin;   Drug: docetaxel;   Other: Correlative Studies
Sponsors:   Ohio State University Comprehensive Cancer Center;   National Comprehensive Cancer Network
Not yet recruiting - verified January 2014

Condition:   Metastatic Prostate Cancer
Interventions:   Drug: Docetaxel, prednisone, abiraterone;   Drug: Docetaxel, prednisone
Sponsor:   Spanish Oncology Genito-Urinary Group
Not yet recruiting - verified January 2014

Condition:   Advanced Prostate Cancer
Interventions:   Drug: BKM 120;   Drug: Cabazitaxel
Sponsors:   SCRI Development Innovations, LLC;   Novartis
Not yet recruiting - verified January 2014

Condition:   Non-Small-Cell Lung Cancer
Interventions:   Drug: Erlotinib;   Drug: Gefitinib;   Drug: Icotinib;   Drug: Docetaxel;   Drug: Pemetrexed;   Drug: Platinum (cisplatin or carboplatin);   Drug: Erlotinib;   Drug: Gefitinib;   Drug: Icotinib
Sponsor:   Qilu Hospital
Active, not recruiting - verified January 2014

Conditions:   Gastric Cancer;   Peritoneal Carcinomatosis
Intervention:   Drug: Intraperitoneal docetaxel
Sponsors:   The University of Hong Kong;   Taiho Pharma Ltd Co
Recruiting - verified December 2013

Condition:   Breast Cancer
Interventions:   Drug: Perjeta (pertuzumab);   Drug: Herceptin (trastuzumab);   Drug: docetaxel, paclitaxel, or nab-paclitaxel (Taxane chemotherapy)
Sponsor:   Hoffmann-La Roche
Recruiting - verified December 2013

Condition:   Nasopharyngeal Carcinoma
Interventions:   Drug: Gemcitabine and cisplatin;   Drug: Docetaxel, cisplatin and 5-Fluorouracil
Sponsor:   Cancer Hospital of Guangxi Medical University
Not yet recruiting - verified December 2013